Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

IIL's Combo Vaccine Wins Big Indian Tender, But Pentavalent Concerns Linger

Executive Summary

State-owned Indian Immunologicals Ltd., one of the local companies aiming to challenge the dominance of multinationals in the domestic Indian vaccine market, has come up with a low-priced five-in-one jab for children that the government is including in its massive national immunization program.

You may also be interested in...



IIL-Griffith Univ Readying Reasonably Priced COVID-19 Vaccine

The entry of India’s state-owned Indian Immunologicals and partner Griffith University in the COVID-19 vaccine race could potentially disrupt pricing dynamics. The alliance is developing a live-attenuated, single dose vaccine, which it hopes will be ready for launch in 18-24 months.

Panacea-Serum Team Up To Take Six-In-One Vaccine Global

Panacea Biotec has allied with the world’s largest-vaccine maker, the Serum Institute of India, to ramp up production of a six-in-one jab aimed at preventing killer diseases like polio and diphtheria and target a global market estimated to be worth over $1.25bn annually.

Challenges Abound As India Seeks To Raise Immunization Rate

India's health minister has announced an ambitious target of ensuring a full child immunization rate of 95% in the next 18 months, up from an overall rate of 65% now, and has appealed to the private sector to help achieve the goal.

Topics

Related Companies

UsernamePublicRestriction

Register

SC066183

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel